Archives: Press Releases
Alivexis Announces Receipt of Intention to Exercise Option Right from Astellas Pharma Inc. for Collaboration on Novel Drug Target
News -
02 September, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura) is pleased to announce they have received a notice from Astellas Pharma Inc. (“Astellas”) to exercise the option right granted under a Research Collaboration Agreement, executed on June 17th 2024. This agreement focused on identifying small molecule compounds targeting a new drug target selected by ...continuedNotice of Selection for the Ministry of Economy, Trade and Industry’s Domestic Generative AI Development Strengthening Project “GENIAC”
News -
15 July, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, is pleased to announce that it has been selected for the third round of the Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development Organization (NEDO)’s Generative AI Accelerator Challenge (GENIAC) project, ...continuedAlivexis to Present at the 2025 BIO International Convention
News -
27 May, 2025 -
Alivexis, Inc. (“Alivexis”), a preclinical-stage computation-driven drug discovery company, will present at the 2025 BIO International Convention being held June 16-19, 2025 in Boston, MA. The presentation will take place on Tuesday, June 17 at 3:30PM in Room 153C at the Boston Convention & Exhibition Center. The corporate update will highlight Alivexis’ updates and progress ...continuedAlivexis To Present at GTC 2025 Japan AI Day
News -
11 March, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces that its computation chemistry platform technology will be presented at NVIDIA’s GTC 2025 Japan AI Day to be held on March 21, 2025 JST (March 20, 2025 PDT). GTC is a global conference for cutting-edge AI and ...continuedAlivexis Raises $0.7M USD Series D in Second Close
News -
03 March, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces the second closing of its Series D round in the amount of 100M JPY (approximately $0.7M USD). Investor participating in the second closing is Ohara Pharmaceutical Co., Ltd. (Headquartered in Koga City, Shiga Prefecture; CEO Seiji Ohara). ...continuedPairMap: Revolutionizing Drug Discovery with Precise Energy Calculations
News -
12 February, 2025 -
Study unlocks new frontiers in drug design by introducing intermediates in energy perturbation calculations Precise calculations of binding free energy are pivotal in reducing the high costs and inefficiencies of drug discovery. A recent study presents PairMap, an innovative computational tool that introduces intermediates for complex compound transformations. This improves the accuracy of energy ...continuedAlivexis Raises $5.1M USD Series D in First Close
News -
07 January, 2025 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces the first closing of its Series D round in the amount of 800M JPY (approximately $5.1M USD). Investors participating in the first closing include funds managed by JIC Venture Growth Investments Co., Ltd., DBJ Capital Co., Ltd., ...continuedAlivexis announces publication of a research article on its ground-breaking ModBind™ simulation technology
News -
20 December, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura, “Alivexis”) a preclinical-stage computation-driven drug discovery firm, announces that a research article entitled “ModBind, a Rapid Simulation-Based Predictor of Ligand Binding and Off-Rates” by William Sinko et. al. has been published in the Journal of Chemical Information and Modeling. This article describes the methodology, validation, ...continuedAlivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo
News -
28 October, 2024 -
Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S.Roy Kimura, “Alivexis”), a preclinical stage technology-driven drug discovery company, will present ModBind™, our drug discovery platform at MACNICA, Inc. booth at the 5th AI EXPO Tokyo held at Makuhari Messe, Tokyo on November 20th-22nd, 2024. The AI EXPO Tokyo is the largest trade show about AI in ...continuedCathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis～Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis～
News -
23 August, 2024 -
Alivexis, Inc. and Hokkaido University today announced the publication of a joint research article entitled “Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders,” published in Nature Communications on August 22, 2024. The research, led by Assistant Professor Yuka Nishibata, Dr. Sakiko Masuda, and Professor Akihiro Ishizu of the Graduate School ...continued